Amador Bioscience Opens New State-of-the-Art GxP Facility in Maryland

Germantown, Md.: Amador Bioscience, a global translational and clinical research CRO, is pleased to announce the grand opening of its GxP lab in Germantown, Maryland, on October 28, 2022. The 10,000+ square foot bioanalytical laboratory joins the company’s other facilities, which opened earlier this year in Belgium, China, and Ann Arbor, Michigan.  

Friday’s grand opening celebration and ribbon cutting included several distinguished guests from leading biopharmaceutical companies, the Belgium embassy, FDA, and the local Maryland community, including:

• Admiral Estella Jones, DVM, Deputy Director, Office of Counterterrorism and Emerging Threats, Office of the Chief Scientist, Office of the Commissioner, Food and Drug Administration
• John Baekelmans, Belgium Flanders Investment & Trade Science and Technology Counselor
• Bart Boschmans, Belgium Flanders Investment & Trade Economic Counselor
• Marc Elrich, Montgomery County Executive
• Dr. Lorin Roskos, Senior Vice President, Exelixis
• Dr. Koustubh Ranade, Vice President & Head of Translational Medicine, Immunocore
• Dr. Binodh DeSilva, Vice President, Bristol Myers Squibb; President of American Association of Pharmaceutical Scientists (2017)
• Dr. Honghui Zhou, Vice President, Head of Clinical Pharmacology and Toxicology, Kira Pharmaceuticals
  
  

Founded in 2018, Amador’s vision is to be the leading global partner for biotherapeutics clinical development success for companies developing novel biotherapeutics. Over the last four years, the company has laid a foundation for clinical-stage development in several biotech hubs, supporting the industry worldwide from pre-clinical development to successful market approval.

“Our company’s values of integrity, excellence, collaboration, and courage are vital components in directing how we are achieving this mission here in Maryland and around the world,” Xiaomin Chen, MBA, Chief Operations Officer at Amador shared at the opening celebration. “We are confident that our world-class bioanalysis and biomarker, and clinical development capabilities, and the strong scientific skill sets and experience of our employees — now and in the future — will propel our local biopharmaceutical companies toward their development goals.”

The grand opening of Amador’s lab on the growing and thriving I-270 corridor highlights a major milestone in the company’s journey. Under the guidance of Dr. Meina Liang, Chief Technology Officer and President of Bioanalysis and Biomarkers at Amador Bioscience, and Rafiq Islam, Vice President of Bioanalysis and Biomarkers in Maryland, the new lab will employ over 100 scientists by the end of 2023.

The Maryland facility — together with the company’s other global sites and teams specialized in bioanalysis and biomarkers, clinical pharmacology, biometrics, regulatory affairs, and clinical research — provides Amador’s clients with an integrated solution for drug development.

Specifically, the facility in Maryland offers advanced bioanalytical technologies such as flow cytometry, digital PCR, qPCR, and LCMS, as well as ligand binding assay and cell-based assay capabilities. These state-of-the-art technologies allow Amador’s expert scientific team to devise bioanalytical strategies that minimize risk and bring investigational drugs to market safely and efficiently.

With an additional 10,400 square foot expansion planned for early 2023, Amador will quickly make space for 75 more scientists to join its organization in Germantown, Maryland. The next major step in the company’s expansion includes opening another GxP bioanalytical lab in Pleasanton, California, by December 2022.

For further information please contact our team or visit amadorbioscience.com.